Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441116 | 0.89 | MEN1 (0.48) | MEN1MAPTKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL5445745 | 0.85 | MALT1 (0.42) | TDP1 | |
| SCHEMBL5446647 | 0.84 | CFTR (0.48) | NPSR1HTT | |
| SCHEMBL3877888 | 0.84 | HRH4 (0.47) | TRPV1L3MBTL1 | |
| SCHEMBL5449419 | 0.83 | CFTR (0.47) | CTSLCTSBCTSKHTT | |
| SCHEMBL5448937 | 0.81 | GBA1 (0.48) | CTSLCTSBCTSKMEN1MAPT | |
| SCHEMBL5453975 | 0.77 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL5451291 | 0.76 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL14581609 | 0.76 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL5449461 | 0.76 | TRPV1 (0.52) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | claimed |
| EP-1651636-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007646-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | CTSL 2271/4885CTSB 1741/4885CTSK 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.